ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

This study is tracking biological markers in the blood to understand how a drug called ofatumumab changes the course of relapsing-remitting multiple sclerosis (MS) — a type of MS where symptoms come and go. Researchers want to find measurable signs in the blood that show whether the treatment is working. **You may be eligible if...** - You are an adult with active relapsing-remitting MS (diagnosed using 2017 criteria) - Your doctor has already decided to prescribe ofatumumab for you as part of your regular care, but you haven't started it yet - Your MS disability score (EDSS) is between 0 and 7 - You can understand written and spoken English or French - You can provide blood samples **You may NOT be eligible if...** - You have primary or secondary progressive MS without relapses - You are pregnant or breastfeeding - You have another condition that could interfere with the study Talk to your doctor to see if this trial is right for you.